MAPT and Alzheimer disease: Since, diagnosis of AD based on clinical criteria alone is uncertain (Monsell et al., 2015) we were careful to use specimens from individuals whose clinical diagnosis was confirmed by the best current biomarkers – CSF Aβ42 and tau.